StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Investment analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH stock opened at $0.01 on Friday. The stock has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The company has a 50 day moving average price of $0.03 and a 200 day moving average price of $0.04. Bellerophon Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.02.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.